Synthesis and tyrosine kinase inhibitory activity of a series of 2- amino-8H-pyrido[2,3-d]pyrimidines: Identification of potent, selective platelet-derived growth factor receptor tyrosine kinase inhibitors

Journal of Medicinal Chemistry

Volumn 41, Issue 22, 1998, Pages 4365-4377

  Boschelli, Diane H ^a   Wu, Zhipei ^a   Klutchko, Sylvester R ^a   Showalter, H D Hollis ^a   Hamby, James M ^a   Lu, Gina H ^a   Major, Terry C ^a   Dahring, Tawny K ^a   Batley, Brian ^a   Panek, Robert L ^a   Keiser, Joan ^a   Hartl, Brian G ^a   Kraker, Alan J ^a   Klohs, Wayne D ^a   Roberts, Bill J ^a   Patmore, Sandra ^a   Elliott, William L ^a   Steinkampf, Randy ^a   Bradford, Laura A ^a   Hallak, Hussein ^a   Doherty, Annette M ^a   more..

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 DIETHYLAMINOETHOXY)PHENYLAMINO] 8 ETHYL 6 PHENYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 2 AMINO 6 (2,6 DICHLOROPHENYL) 8 METHYL 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; 2 AMINO 8H PYRIDO[2,3 D]PYRIMIDINE DERIVATIVE; FIBROBLAST GROWTH FACTOR RECEPTOR; ONCOPROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG SCREENING; DRUG SYNTHESIS; GLIOMA; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PROTEIN PHOSPHORYLATION; RAT; SMOOTH MUSCLE FIBER; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

3T3 CELLS; ANIMALS; BIOLOGICAL AVAILABILITY; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME INHIBITORS; HUMANS; MALE; MICE; MICE, NUDE; MUSCLE, SMOOTH, VASCULAR; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PYRIDONES; PYRIMIDINES; RATS; RATS, WISTAR; RECEPTORS, FIBROBLAST GROWTH FACTOR; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 15644374929     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm980398y     Document Type: Article

References (57)

1. Levitzki, A.; Gazit, A. Tyrosine Kinase Inhibition: An Approach to Drug Development. Science 1995, 267, 1782-1788.
2. Traxler, P. M. Protein Tyrosine Kinase Inhibitors in Cancer Treatment. Exp. Opin. Ther. Patents 1997, 7, 571-588.
3. Shawver, L. K.; Lipson, K. E.; Fong, A. T.; McMahon, G.; Plowman, G. D.; Strawn, L. M. Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis. Drug Discovery Today 1997, 2, 50-63.
4. Folkman, J. Angiogenesis in Cancer, Vascular, Rheumatoid and other Disease. Nature Medicine 1995, 1, 27-31.
5. Mattsson, E.; Clowes, A. W. Current Concepts in Restenosis Following Balloon Angioplasty. Trends Cardiovas. Med. 1995, 5, 200-204.
6. Shaw, L. A.; Rudin, M.; Cook, N. S. Pharmacological Inhibition of Restenosis: Learning from Experience. Trends Pharm. Sci. 1995, 16, 401-404.
7. Raines, E. W.; Ross, R. Multiple Growth Factors are Associated with Lesions of Atherosclerosis: Specificity or Redunancy? BioEssays 1996, 18, 271-282.
8. Bridges, A. J. The Epidermal Growth Factor Receptor Family of Tyrosine Kinases and Cancer: Can an Atypical Exemplar be a Sound Therapeutic Target? Curr. Med. Chem. 1996, 3, 167-194.
9. Hanks, S. K.; Quinn, A. M.; Hunter, T. The Protein Kinase Family: Conserved Features and Deduced Phylogeny of the Catalytic Domains. Science 1988, 242, 42-52.
10. Maguire, M. P.; Sheets, K. R.; McVety, K.; Spada, A. P.; Zilberstein, A. A New Series of PDGF Receptor Tyrosine Kinase Inhibitors: 3-Substituted Quinoline Derivatives. J. Med. Chem. 1994, 37, 2129-2137.
11. Dolle, R. E.; Dunn, J. A.; Bobko, M.; Singh, B.; Kuster, J. E.; Baizman, E.; Harris, A. L.; Sawutz, D. G.; Miller, D.; Wang, S.; Faltynek, C. R.; Xie, W.; Sarup, J.; Bode, D. C.; Pagani, E. D.; Silver, P. J. 5,7-Dimethoxy-3-(4-pyridinyl)quinoline Is a Potent and Selective Inhibitor of Human Vascular β-Type Platelet-Derived Growth Factor Receptor Tyrosine Kinase. J. Med. Chem. 1994, 37, 2627-2629.
12. Buchdunger, E.; Zimmerman, J.; Mett, H.; Meyer, T.; Muller, M.; Regenass, U.; Lydon, N. B. Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-Phenylaminopyrimidine Class. Proc. Natl. Acad. Sci. U.S.A. 1995, 92, 2558-2562.
13. Zimmerman, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B.; Traxler, P. Phenylamino-pyrimidine (PAP)-Derivatives: A New Class of Potent and Highly Selective PDGF-Receptor Autophosphorylation Inhibitors. Bioorg. Med. Chem. Lett. 1996, 6, 1221-1226.
14. Gazit, A.; App, H.; McMahon, G.; Chen, J.; Levitzki, A.; Bohmer, F. D. Tyrphostins. 5. Potent Inhibitors of Platelet-Derived Growth Factor Receptor Tyrosine Kinaee: Structure- Activity Relationships in Quinoxalines, Quinolines, and Indole Tyrphostins. J. Med. Chem. 1996, 39, 2170-2177.
15. Yagi, M.; Kato, S.; Kobayashi, Y.; Kubo, K.; Oyama, S.; Shimizu, T.; Nishitoba, T.; Isoe, T.; Nakamura, K.; Ohasi, H.; Kobayashi, N.; Iinuma, N.; Osawa, T.; Onose, R.; Osada, H. Selective Inhibition of Platelet-Derived Growth Factor (PDGF) Receptor Autophosphorylation and PDGF- Mediated Cellular Events by a Quinoline Derivative. Exp. Cell Res. 1997, 234, 285-292.
16. Kubo, K.; Shimizu, T.; Ohyama, S.; Murooka, H.; Nishitoba, T.; Kato, S.; Kobayashi, Y.; Yagi, M.; Isoe, T.; Nakamura, K.; Osawa, T.; Izawa, T. A Novel Series of 4-Phenoxyquinolines: Potent and Highly Selective Inhibitors of PDGF Receptor Autophosphorylation. Bioorg. Med. Chem. Lett. 1997, 7, 2935-2940.
17. Shawyer, L. K.; Schwartz, D. P.; Mann, E.; Chen, H.; Tsai, J.; Chu, L.; Taylorson, L.; Longhi, M.; Meredith, S.; Germain, L.; Jacobs, J. S.; Tang, C.; Ullrich, A.; Berens, M.; Hersh, E.; McMahon, G.; Hirth, K. P.; Powell, T. J. Inhibition of Platelet-derived Growth Factor-Mediated Signal Transduction and Tumor Growth by N-[4-(trifluoromethyl)phenyl] 5-methylisoxazole-4-carboxamide. Clin. Cancer Res. 1997, 3, 11167-1177.
18. Mohammadi, M.; McMahon, G.; Sun, L.; Tang, C.; Hirth, P.; Yeh, B. K.; Hubbard, S. R.; Schlessinger, J. Structures of the Tyrosine Kinase Domain of Fibroblast Growth Factor Receptor in Complex with Inhibitors. Science 1997, 276, 955-960.
19. Gazit, A.; Chan, J.; App, H.; McMahon, G.; Hirth, P.; Chen, I.; Levitzki, A. Tyrphostins IV-Highly Potent Inhibitors of EGF Receptor Kinase. Structure-Activity Relationship Study of 4-Anilidoquinazolines. Bioorg. Med. Chem. 1996, 4, 1203-1207.
20. Traxler, P. M.; Furet, P.; Mett, H.; Buchdunger, E.; Meyer, T.; Lydon, N. 4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase. J. Med. Chem. 1996, 39, 2285-2292.
21. Traxler, P.; Bold, G.; Frei, J.; Lang, M.; Lydon, N.; Mett, H.; Buchdunger, E.; Meyer, T.; Mueller, M.; Furet, P. Use of a Pharmacophore Model for the Design of EGF-R Tyrosine Kinase Inhibitors: 4-(Phenylamino)pyrazolo[3,4-d]pyrimidines. J. Med. Chem. 1997, 40, 3601-3616.
22. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Zulli, A. L.; Hsu, C.-H. J.; Zilberstein, A.; Johnson, S. E.; Hook, L. E.; Jacoski, M. V. The Preparation and SAR of 4-(Anilino), 4-(Phenoxy), and 4-(Thiophenoxy)-quinazolines: Inhibitors of p561ck and EGF-R Tyrosine Kinase Activity. Bioorg. Med. Chem. Lett. 1997, 7, 417-420.
23. Hanke, J. H.; Gardner, J. P.; Dow, R. L.; Changelian, P. S.; Brissette, W. H.; Weringer, E. J.; Pollok, B. A.; Connelly, P. A. Discovery of a Novel, Potent, and Src Family selective Tyrosine Kinase Inhibitor. J. Biol. Chem. 1996, 271, 695-701.
24. Zimmerman, J.; Buchdunger, E.; Mett, H.; Meyer, T.; Lydon, N. B. Potent and Selective Inhibitors of the abl-Kinase: Phenylaminopyrimidine (PAP) Derivatives. Bioorg. Med. Chem. Lett. 1997, 7, 187-192.
25. Myers, M. R.; Setzer, N. N.; Spada, A. P.; Persons, P. E.; Ly, C. Q.; Maguire, M. P.; Zulli, A. L.; Cheney, D. L.; Zilberstein, A.; Johnson, S. E.; Franks, C. F.; Mitchell, K. J. The Synthesis and SAR of New 4-(N-Alkyl-N-phenyl)amino-6,7-dimethoxyquinazolines and 4-(N-Alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, Inhibitors of CSF-1R Tyrosine Kinase Activity. Bioorg. Med. Chem. Lett. 1997, 7, 421-424.
26. Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Barker, A. J.; Brown, D. S. Epidermal Growth Factor Receptor Tyrosine Kinase: Structure-Activity Relationships and Antitumor Activity of Novel Quinazolines. Bioorg. Med. Chem. Lett. 1997, 7, 2723-2728.
27. Rewcastle, G. W.; Denny, W. A.; Bridges, A. J.; Zhou, H.; Cody, D. R.; McMichael, A.; Fry, D. W. Tyrosine Kinase Inhibitors: 5. Synthesis and Structure-Activity Relationships for 4-[(Phenyl-methyl)amino]- and 4-(Phenylamino)quinazolines as Potent Adenosine 5′-Triphosphate Binding Site Inhibitors of the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor. J. Med. Chem. 1995, 35, 3482-3487.
28. Thompson, A. M.; Bridges, A. J.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors: 7. 7-Amino-4-(phenylamino)-and 7-Amino-4-[(phenylmethyl)amino]pyrido[4,3-d]pyrimidines: A New Class of Inhibitors of Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1995, 38, 3780-3788.
29. Bridges, A. J.; Zhou, H.; Cody, D. R.; Rewcastle, G. W.; Mc-Michael, A.; Showalter, H. D. H.; Fry, D. W.; Kraker, A. J.; Denny, W. A. Tyrosine Kinase Inhibitors: 8. An Unusually Steep Structure-Activity Relationship for Analogues of 4-(3-Bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a Potent Inhibitor of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 267-276.
30. Rewcastle, G. W.; Palmer, B. D.; Bridges, A. J.; Showalter, H. D. H.; Sun, L.; Nelson, J.; McMichael, A.; Kraker, A. J.; Fry, D. W.; Denny, W. A. Tyrosine Kinase Inhibitors: 9. Synthesis and Evaluation of Fused Tricyclic Quinazoline Analogues as ATP Site Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 918-928.
31. Rewcastle, G. W.; Palmer, B. D.; Thompson, A. M.; Bridges, A. J.; Cody, D. R.; Zhong, H.; Fry, D. W.; McMichael, A.; Denny, W. A. Tyrosine Kinase Inhibitors: 10. Isomeric 4-[(3-Bromophenyl)amino]pyrido[d]pyrimides are Potent ATP Binding Site Inhibitors of the Tyrosine Kinase Function of the Epidermal Growth Factor Receptor. J. Med. Chem. 1996, 39, 1823-1835.
32. Palmer, B. D.; Trumpp-Kallmeyer, S.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Denny, W. A. Tyrosine Kinase Inhibitors: 11. Soluble Analogues of Pyrrolo- and Pyrazoloquinazolines as Epidermal Growth Factor Receptor Inhibitors: Synthesis, Biological Evaluation, and Modeling of the Mode of Binding. J. Med. Chem. 1997, 40, 1519-1529.
33. Rewcastle, G. W.; Bridges, A. J.; Fry, D. W.; Rubin, R.; Denny, W. A. Tyrosine Kinase Inhibitors: 12. Synthesis and Structure-Activity Relationships for 6-Substituted 4-(Phenylamino)pyrimido[5,4-d]pyrimidines Designed as Inhibitors of the Epidermal Growth Factor Receptor. J. Med. Chem. 1997, 40, 1820-1826.
34. Thompson, A. M.; Murray, D. K.; Fry, D. W.; Nelson, J. M.; Showalter, H. D. H.; Roberts, B. J.; Vincent, P. W.; Denny, W. A. Tyrosine Kinase Inhibitors: 13. Structure-Activity Relationships for Soluble 7-Substituted 4-[(3-Bromophenyl)amino]pyrido-[4,3-d]pyrimidines as Inhibitors of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor. J. Med. Chem. 1997, 40, 3915-1925.
35. Rewcastle, G. W.; Murray, D. K.; Elliot, W. L.; Fry, D. W.; Howard, C. T.; Nelson, J. M.; Roberts, B. J.; Vincent, P. W.; Showalter, H. D. H.; Winters, R. T.; Denny, W. A. Tyrosine Kinase Inhibitors: 14. Structure-Activity Relationships for Methylamino-Substituted Derivatives of 4-[(3-Bromopheny)-amino]-6-(methylamino)-pyrido[4,3-d]pyrimidine (PD 158780), a Potent and Specific Inhibitor of the Tyrosine Kinase Activity of Receptors of the EGF Family of Growth Factors. J. Med. Chem. 1998, 47, 742-751.
36. Hamby, J. M.; Connolly, C. J. C.; Schroeder, M. C.; Winters, R. T.; Showalter, H. D. H.; Panek, R. L.; Major, T. C.; Olsewski, B.; Ryan, M. J.; Dahring, T.; Lu, G. H.; Keiser, J.; Amar, A.; Shen, C.; Kraker, A. J.; Slintak, V.; Nelson, J. M.; Fry, D. W.; Bradford, L.; Hallak, H.; Doherty, A. M. Structure-Activity Relationships for a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors. J. Med. Chem. 1997, 40, 2296-2303.
37. Connolly, C. J. C.; Hamby, J. M.; Schroeder, M. C.; Barvian, M.; Lu, G. H.; Panek, R. L.; Amar, A.; Shen, C.; Kraker, A. J.; Fry, D. W.; Klohs, W. D.; Doherty, A. M. Discovery and Structure-Activity Relationships of a Novel Series of Pyrido[2,3-d]pyrimidine Tyrosine Kinase Inhibitors. Bioorg. Med. Chem. Lett. 1997, 7, 2415-2420.
38. Barvian, M. R.; Panek, R. L.; Lu, G. H.; Kraker, A. J.; Amar, A.; Hartl, B.; Hamby, J. M.; Showalter, H. D. H. 1-Oxo-3-aryl-1H-indene-2-carboxylic Acid Derivatives as Selective Inhibitors of Fibroblast Growth Factor Receptor-1 Tyrosine Kinase. Bioorg. Med. Chem. Lett. 1997, 7, 2903-2908.
39. Waterfield, M. D.; Scrace, G. T.; Whittle, N.; Stroobant, P.; Johnsson, A.; Wasteson, A.; Westermark, B.; Heldin, C.-H.; Huang, J. S.; Deuel, T. F. Platelet-derived Growth Factor is Structurally Related to the Putative Transforming Protein p28sis of Simian Sarcoma Virus. Nature 1983, 304, 35-39.
40. Doolittle, R. F.; Hunkapiller, M. W.; Hood, L. E.; Devare, S. G.; Robbins, K. C.; Aaronson, S. A.; Antoniades, H. N. Simian Sarcoma Virus one Gene, v-sis, is Derived from the Gene (or genes) Encoding Platelet-derived Growth Factor. Science 1983, 221, 275-277.
41. Nister, M.; Libermann, T. A.; Betsholtz, C.; Pettersson, M.; Claesson-Welsh, L.; Heldin, C.-H.; Schlessinger, J.; Westermark, B. Expression of Messenger RNAs for Platelet-derived Growth Factor and Transforming Growth Factor-α and Their Receptors in Human Maligant Glioma Cell Lines. Cancer Res. 1988, 48, 3910-3918.
42. Nister, M.; Claesson-Welsh, L.; Eriksson, A.; Heldin, C.-H.; Westermark, B. Differential Expression of Platelet-derived Growth Factor Responses in Human Malignant Glioma Cell Lines. Cancer Res. 1991, 51, 16755-16763.
43. Hermanson, M.; Funa, K.; Hartman, M.; Claesson-Welsh, L.; Heldin, C.-H.; Westermark, B.; Nister, M. Platelet-derived Growth Factor and Its Receptors in Human Glioma Tissue: Expression of Messenger RNA and Protein Suggests the Presence of Autocrine and Paracrine Loops. Cancer Res. 1992, 52, 3213-3219.
44. Fleming, T. P.; Matsui, T.; Heidaran, M. A.; Molloy, C. J.; Artrip, J.; Aaronson, S. A. Demonstration of an Activated Platelet-derived Growth Factor Autocrine Pathway and its Role in Human Tumor Cell Proliferation in Vitro. Oncogene 1992, 7, 1355-1359.
45. Strawn, L. M.; Mann, E.; Elliger, S. S.; Chu, L. M.; Germain, L. L.; Niederfellner, G.; Ullrich, A.; Shawver, L. K. Inhibition of Glioma Cell Growth by a Truncated Platelet-derived Growth Factor-β Receptor. J. Biol. Chem. 1994, 269, 21215-21222.
46. Klutchko, S. R.; Hamby, J. M.; Boschelli, D. H.; Wu, Z.; Kraker, A. J.; Amar, M.; Hartl, B. G.; Shen, C.; Klohs, W. D.; Steinkampf, R. W.; Driscoll, D. L.; Nelson, J. M.; Elliott, W. L.; Roberts, B. J.; Stoner, C. L.; Vincent, P. W.; Dykes, D. J.; Panek, R. L.; Lu, G. H.; Major, T. C.; Dahring, T. K.; Hallak, H.; Bradford, L. A.; Showalter, H. D. H.; Doherty, A. M. 2-Substituted Aminopyrido-[2,3-d]pyrimidin-7(8H)-ones. Structure-Activity Relationships Against Selected Tyrosine Kinases and in Vitro and in Vivo Anticancer Activity. J. Med. Chem. 1998, 41, 3276-3292.
47. Panek, R. L.; Lu, G. H.; Klutchko, S. R.; Batley, B. L.; Dahring, T. K.; Hamby, J. M.; Hallak, H.; Doherty, A. M.; Kei J. A. In Vitro Pharmocological Characterization of PD 166285, a New Nanomolar Potent and Broadly Active Protein Tyrosine Kinase Inhibitor. J. Pharmacol. Exp. Ther. 1998, 253, 1433-1444.
48. Dahring, T. K.; Lu, G. H.; Hamby, J. M.; Batley, B. L.; Kraker, A. J.; Panek, R. L. Inhibition of Growth Factor-mediated Tyrosine Phosphorylation in Vascular Smooth Muscle by PD 089828, a New Synthetic Protein Tyrosine Kinase Inhibitor. J. Pharmacol. Exp. Ther. 1997, 281, 1446-1456.
49. Trumpp-Kallmeyer, S.; Rubin, J. R.; Humblet, C.; Hamby, J. M.; Showalter, H. D. H. Development of a Binding Model to Protein Tyrosine Kinases for Substituted Pyrido[2,3-d]pyrimidine Inhibitors. J. Med. Chem. 1998, 41, 1752-1763.
50. For the initial report of this work, see: Wu, Z.; Boschelli, D. H.; Klutchko, S. R.; Lu, G.; Panek, R. L.; Kraker, A. J.; Doherty, A. M. Synthesis and Tyrosine Kinase Inhibitory Activity of a Series of 2-Amino-8H-pyrido[2,3-d]pyrimidines. 213th National Meeting of the American Chemical Society, San Francisco, CA, 1997; Abstract #201.
51. Buchi, J.; Enezian, J.; Enezian, G.; Valette, G.; Pattani, C. Synthesis and Action of Local Anesthetics Derived from Procaine. Helv. Chim. Acta 1980, 43, 1971-1979.
52. Santilli, A. A.; Kim, D. H.; Wanser, S. V. Thieno[2,3-d]pyrimidines. I. A New Method for the Preparation of Esters and Amides of Thieno[2,3-d]pyrimidine-6-carboxylic Acids. J. Heterocycl. Chem. 1971, 8, 445-453.
53. Vishwakarama, L. C.; Stringer, O. D.; Davis, F. A. (±) trans-2-(Phenylsulfonyl)-3-phenyloxaziridine. Org. Synth. 1987, 66, 203-210.
54. For assay protocols, see refs 36, 37, 47, and 48.
55. Schabel, F. M., Jr.; Griswold, D. P., Jr.; Laster, W. R., Jr.; Corbett, T. H.; Lloyd, H. H. Quantitative Evaluation of Anticancer Agent Activity in Experimental Animals. Pharmacol. Ther. 1977, 1, 411-435.
56. Elliott, W. L.; Howard, C. T.; Dykes, D. J.; Leopold, W. R. Sequence and Schedule-dependent Synergy of Trimetrexate in Combination with 5-Fluorouracil in Vitro and in Mice. Cancer Res. 1989, 49, 5586-5590.
57. Elliott, W. L.; Roberts, B. J.; Howard, C. T.; Leopold, W. R., III. Chemotherapy with CI-973 ([SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato (2-)]2-methyl-1,4-butanediamine-N,N')platinum, NK121) in Combination with Standard Agents against Murine Tumors in Vivo. Cancer Res. 1994, 54, 4412-4418.